

Technology Appraisal Committee D Interests Register

Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID3786]

Publication Date: 14/10/2020

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Amanda Matse-Orere	TAC D Committee member	Direct financial	Works for comparator company, Roche.	NA	22/07/2020	NA	It was agreed that this conflict would prevent Mrs Matse-Orere from participating in this discussion.
Dr Matt Bradley	TAC D Committee member	Direct financial	Holds shares in AstraZeneca	NA	22/07/2020	NA	It was agreed that this conflict would prevent Dr Bradley from participating in this discussion